Substance Name: Ipilimumab [USAN:INN]
RN: 477202-00-9
UNII: 6T8C155666
Notes
- An anti-CTLA-4 ANTIGEN monoclonal antibody initially indicated for the treatment of certain types of metastatic MELANOMA. Its mode of actions may include blocking of CTLA-4 mediated inhibition of CYTOTOXIC T LYMPHOCYTES, allowing for more efficient destruction of target tumor cells.
- An anti-cytotoxic T lymphocyte-associated antigen 4 antibody for treatment of metastatic melanoma and other cancers.
NCI: A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways. (NCI Thesaurus)
Molecular Formula
- C6472-H9972-N1732-O2004-S40
Classification Codes
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Treatment of Oncology Disease and HIV Infection
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Names and Synonyms
Name of Substance
- Ipilimumab
- Ipilimumab [USAN:INN]
MeSH Heading
- Ipilimumab
Synonyms
- Anti-CTLA4
- Immunoglobulin G1, anti-(human CTLA-4 (antigen)) (human gamma1-chain), disulfide with human kappa-chain, dimer
- Ipilimumab
- MDX 010
- MDX-010
- MDX-CTLA 4
- MDX-CTLA-4
- Monoclonal antibody MDX-010
- UNII-6T8C155666
- Yervoy
Registry Numbers
CAS Registry Number
- 477202-00-9
FDA UNII
- 6T8C155666
Other Registry Number
- 799813-32-4
System Generated Number
- 0477202009